Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





INSOLUBLE TUNGSTEN								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 7440-33-7; **Chemical Formula:** W
Previously, OSHA had no exposure limits for insoluble tungsten and its compounds. The ACGIH has established 5 mg/m3 as an 8-hour TWA and 10 mg/m3 as a short-term exposure limit for these substances. NIOSH recommends a limit of 5 mg/m3 as a 10-hour TWA. The proposed PEL for this group of substances was 5 mg/m3 as an 8-hour TWA and 10 mg/m3 as a 15-minute STEL. NIOSH (Ex. 8-47) concurred with OSHA’s proposed limits. The final rule promulgates a 5 mg/m3 8-hour TWA and a 10 mg/m3 5-minute STEL, measured as tungsten. Tungsten is a gray, hard metal.
Rats fed a diet containing 0.5 percent insoluble tungsten compounds died, and another group of rats fed 0.1 percent of these compounds suffered noticeable weight loss (Kinard and Van de Erve 1941/Ex. 1-492). Studies in rats fed tungsten at 2, 5, or 10 percent of their diet showed that females in all dose groups had a 15-percent reduction in weight gain (Kinard and Van de Erve 1943/Ex. 1-493). The intraperitoneal LD(50) for tungsten metal powder in rats was 5 g/kg body weight; survivors showed minor liver and spleen changes at necropsy (Fredrick and Bradley 1946, as cited in ACGIH 1986/Ex. 1-3, p. 614). Studies of the tissues of guinea pigs intratracheally injected with tungsten metal and tungsten carbide revealed moderate interstitial cellular proliferation and no changes, respectively. However, Soviet studies involving similar intratracheal injections showed proliferation of the intra-alveolar septa (Kaplun and Mezentseva 1960, as cited in ACGIH 1986/Ex. 1-3, p. 614). The NIOSH criteria document for tungsten (1977h, as cited in ACGIH 1986/Ex. 1-3, p. 614) reports that Russian investigators found a 9- to 11-percent incidence of pulmonary fibrosis in workers exposed to tungsten (Kaplun and Mezentseva 1959/Ex. 1-961; and Mezentseva 1967, as cited in ACGIH 1986/Ex. 1-3, p. 614). NIOSH (1977h) recommended that the standard for tungsten and its insoluble compounds be set at 5 mg/m3 to protect against pulmonary effects.
Stokinger (in Patty’s Industrial Hygiene and Toxicology, 3rd rev. ed., Vol. 2A, Clayton and Clayton 1981) reported on several epidemiological studies of workers in the “hard metal industry,” in which tungsten carbide is machined. These studies describe a condition known as hard metal disease, which may be accompanied by pulmonary fibrosis. The disease is characterized by a moderate incidence of cough, dyspnea, and wheezing, a high incidence of minor radiological abnormalities with a few instances of marked abnormalities, and development of hypersensitivity asthma in some workers (which may be due to exposure to the cobalt that is used as a binding agent). The disease is progressive and potentially lethal. Stokinger (in Patty’s Industrial Hygiene and Toxicology, 3rd rev. ed., Vol. 2A, Clayton and Clayton 1981, p. 1992) reported that, unlike other lung diseases produced by inorganic dust, there is no correlation between onset of symptoms, length of exposure, and the development of interstitial fibrosis. Analysis of the lung of one worker who had clinical signs and radiological changes showed the presence of large amounts of tungsten with much smaller amounts of other metals.
Mr. H.K. Thompson, Corporate Industrial Hygiene Manager for Caterpillar, Inc. (Ex. 3-349), questioned the need for a STEL for tungsten. OSHA believes that, given the potential seriousness of hard metal disease and the uncertainties regarding the relationship between exposure and response, a short-term limit for tungsten will provide additional assurance that the 8-hour TWA PEL is not exceeded. Therefore, in accordance with OSHA’s policy for establishing STELs in this rulemaking (see Section IV.C.17), OSHA finds that a STEL for tungsten is necessary.
In the final rule, OSHA is establishing an 8-hour TWA of 5 mg/m3 and a STEL of 10 mg/m3 for tungsten and its insoluble compounds, measured as tungsten. The Agency concludes that these limits will substantially reduce the significant risk of pulmonary fibrosis and other lung effects, which constitute material impairments of health that are associated with exposure to this metal and its insoluble compounds at levels above the new PELs.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue